[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Samaddar et al., 2020 - Google Patents

Pathophysiology and potential therapeutic candidates for COVID-19: a poorly understood arena

Samaddar et al., 2020

View HTML
Document ID
9026361162074021301
Author
Samaddar A
Grover M
Nag V
Publication year
Publication venue
Frontiers in pharmacology

External Links

Snippet

Coronavirus disease 2019 (COVID-19), an acute onset pneumonia caused by a novel Betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in the Wuhan City of China in December 2019 and evolved into a global pandemic. To date …
Continue reading at www.frontiersin.org (HTML) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense
    • C12N2770/00011—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA Viruses positive-sense ssRNA Viruses positive-sense
    • C12N2770/24011—Flaviviridae

Similar Documents

Publication Publication Date Title
Esmaeilzadeh et al. Immunobiology and immunotherapy of COVID‐19: A clinically updated overview
Dos Santos Natural history of COVID-19 and current knowledge on treatment therapeutic options
Wong et al. Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses—are we our own worst enemy?
Zhang et al. Current status of potential therapeutic candidates for the COVID-19 crisis
Shah et al. Overview of immune response during SARS-CoV-2 infection: lessons from the past
Lopes-Pacheco et al. Pathogenesis of multiple organ injury in COVID-19 and potential therapeutic strategies
Rojas et al. Convalescent plasma in Covid-19: Possible mechanisms of action
Jafarzadeh et al. Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions
Nelemans et al. Viral innate immune evasion and the pathogenesis of emerging RNA virus infections
Peng Outbreak of COVID-19: An emerging global pandemic threat
Beig Parikhani et al. The inclusive review on SARS-CoV-2 biology, epidemiology, diagnosis, and potential management options
Samaddar et al. Pathophysiology and potential therapeutic candidates for COVID-19: a poorly understood arena
Chen et al. HCV genomic RNA activates the NLRP3 inflammasome in human myeloid cells
Canedo-Marroquin et al. SARS-CoV-2: immune response elicited by infection and development of vaccines and treatments
Velikova et al. Immunological aspects of COVID-19: What do we know?
Lisi et al. Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2
Goodarzi et al. Coronavirus disease 2019 (COVID-19): Immunological approaches and emerging pharmacologic treatments
Das et al. An overview of key potential therapeutic strategies for combat in the COVID-19 battle
Zhand et al. COVID-19: The immune responses and clinical therapy candidates
Soy et al. Pathogenesis and treatment of cytokine storm in COVID-19
Baral et al. Treatment and prevention strategies for the COVID 19 pandemic: a review of immunotherapeutic approaches for neutralizing SARS-CoV-2
Awasthi et al. OUTBREAK of novel corona virus disease (COVID-19): Antecedence and aftermath
Masoomikarimi et al. Advances in immunotherapy for COVID-19: A comprehensive review
de Queiroz et al. Vaccines for COVID-19: perspectives from nucleic acid vaccines to BCG as delivery vector system
Ku et al. Antibody therapies for the treatment of COVID-19